Study wrapper · #1052
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
Rantanen R, Olson C, Raval C Journal of clinical psychopharmacology. 2026.
DOI: 10.1097/jcp.0000000000002241PubMed: 42495981
Editor's note
A single-patient case report describing weight loss on tirzepatide accompanied by a bipolar disorder exacerbation in the context of clozapine therapy. The possible interaction is noteworthy for clinicians, but a case report cannot separate the medication's role from the underlying illness course. No abstract was available to evaluate further detail.
Plain-language abstract
This single case report describes tirzepatide-associated weight loss alongside a worsening of bipolar disorder in a patient also taking clozapine. As a single case, it cannot establish a causal link.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026